Etanercept: A viable treatment option for young children with generalized pustular psoriasis
Open Access
- 12 August 2024
- journal article
- research article
- Published by Wiley in Pediatric Investigation
- Vol. 8 (4) , 295-298
Abstract
No abstract availableFunding Information
- National Key Research and Development Program of China (2023YFC2508101)
This publication has 11 references indexed in Scilit:
- Spesolimab for the Treatment of Generalized Pustular PsoriasisDrugs, 2023
- The update of treatment strategies in pediatrics with generalized pustular psoriasis in ChinaPediatric Investigation, 2023
- Higher Prevalence of Generalized Pustular Psoriasis in Asia? A Population-Based Study Using Claim Data in China and a Systematic ReviewDermatology, 2023
- Treatment Options and Goals for Patients with Generalized Pustular PsoriasisAmerican Journal of Clinical Dermatology, 2022
- Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic DiseaseInternational Journal of Molecular Sciences, 2021
- Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remissionBritish Journal of Dermatology, 2019
- Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T>C (p.Leu27Pro) mutation successfully treated with etanercept and acitretinJAAD Case Reports, 2018
- Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasisJournal of the American Academy of Dermatology, 2016
- Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis FoundationJournal of the American Academy of Dermatology, 2012
- Anti-TNF-α Therapy in Childhood Pustular PsoriasisDermatology, 2006